Immune thrombocytopenic purpura: A rare side effect in a patient treated with Imiquimod for lentigo maligna

Gautschi, 2016, Prognostic markers in lentigo maligna patients treated with imiquimod cream: a long-term follow-up study, J Am Acad Dermatol, 74, 81, 10.1016/j.jaad.2015.08.031 Marsden, 2010, Revised U.K. guidelines for the management of cutaneous melanoma, Br J Dermatol, 163, 238, 10.1111/j.1365-2133.2010.09883.x Tzellos, 2014, Interventions for melanoma in situ, including lentigo maligna, Cochrane Database Syst Rev, 10.1002/14651858.CD010308.pub2 Marsden, 2016, Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study, Br J Dermatol Mora, 2015, A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance, J Am Acad Dermatol, 73, 205, 10.1016/j.jaad.2015.05.022 Kumar, 2011, Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation, Sex Transm Infect, 87, 432, 10.1136/sextrans-2011-050025 Arnold, 2013, Approach to the diagnosis and management of drug-induced immune thrombocytopenia, Transfus Med Rev, 27, 137, 10.1016/j.tmrv.2013.05.005